Vectura Inks Asthma/COPD License Agreement with Janssen – Genetic Engineering & Biotechnology News

Vectura Inks Asthma/COPD License Agreement with Janssen
Genetic Engineering & Biotechnology News
Vectura, a respiratory product development company, has entered a license agreement with Janssen Biotech to exclusively develop anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will initially focus on the development of a …

View full post on asthma – Google News

Aerocrine: Aerocrine signs distribution agreement with third largest chinese … – The Herald | HeraldOnline.com

Aerocrine: Aerocrine signs distribution agreement with third largest chinese
The Herald | HeraldOnline.com
The agreement, effective as of September 24, 2012, gives SPH exclusive rights for import and non-exclusive rights for distribution of Aerocrine's instrument NIOX MINO® and test kits, used for diagnosing and monitoring patients with asthma, on the

and more »

View full post on asthma – Google News

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With … – NASDAQ

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With
NASDAQ
MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary

and more »

View full post on asthma – Google News

AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug – Proactive Investors USA & Canada


Proactive Investors USA & Canada

AstraZeneca, Dynavax amend agreement to accelerate development of asthma drug
Proactive Investors USA & Canada
AstraZeneca (NYSE:AZN) and Dynavax Technologies (NASDAQ:DVAX) announced Wednesday they have amended their collaboration agreement so as to accelerate the development of AZD1419, intended for the treatment of asthma. Under the terms of the agreement,
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for AsthmaMarketWatch (press release)
Dynavax gets $3M in reworked asthma deal with AstraZenecaBizjournals.com (blog)

all 12 news articles »

View full post on asthma – Google News

Kos Pharmaceuticals and SkyePharma terminate license agreement for flutiform – Trading Markets (press release)

Kos Pharmaceuticals and SkyePharma terminate license agreement for flutiform
Trading Markets (press release)
Flutiform is used for adult and adolescent asthma. Under the terms of the agreement, Kos has the right to perform further clinical development for
Abbott, Skyepharma Part Ways On Asthma Drug FlutiformPharmaLive (press release) (subscription)

all 2 news articles »

View full post on asthma – Google News